ISGEC Heavy Engineering Limited: Equity Research Assessment

Analysis Date: 2026-08-12 Current Price: ₹807.0 | Market Cap: ₹7,052 Cr | Trailing P/E: 24.8x

1. Announcement Analysis & Order Book Ramp Math

• Order Book Status: ₹8,958 Cr as of June 30, 2026 (~1.31x TTM revenue of ₹6,819 Cr).
• Fresh Order Intake: ₹2,733 Cr in Q1 FY27 (+31.7% YoY vs ₹2,074 Cr in Q1 FY26).
• Execution Period: 18 to 24 months (2.0 years average cycle for capital goods & turnkey EPC).
• Revenue Conversion:
• TTM Revenue: ₹6,819 Cr
• Year 1 Expected Revenue Growth: ~11.0% (in line with company management guidance of 10-12% for FY27).
• Steady-State Revenue Growth: ~15.0% as higher-margin Dahej skids/modules expansion (₹275 Cr capacity) and expanded Ethanol operations (160 KLPD) ramp up.
• EPS Impact Math:
• Current TTM PAT: ₹284.35 Cr (EPS ₹32.54).
• Operating margins in Manufacturing (13.8% EBIT) outperform EPC (4.7% EBIT).
• A 12-15% revenue expansion combined with product mix shifts toward manufacturing should lift steady-state EPS by ~18% to ₹38.40 - ₹40.00.

2. Industry Context & Quality Evaluation

• Capital Intensity: Medium to High (requires ongoing capex for manufacturing facilities and significant working capital for EPC execution).
• Execution Difficulty: High due to project delays, fixed-price contract risks, and macro cyclicality in core buyer sectors (steel, cement, power).
• Quality Gate: Passed. ROCE stands at 17.0%, D/E at 0.25, and promoter holding is steady at 62.43%.
• Fundamental Grade: B (Constrained by low EPC segment margins and discontinued operations drag).

3. Valuation & Scenario Calibrations

• Base Case (+35% Upside to ~₹1,090): Revenue grows at 12-14% CAGR; manufacturing segment share increases; EPS reaches ~₹45.00 in FY28; valued at 24x forward P/E.
• Bull Case (+70% Upside to ~₹1,370): Rapid execution of ₹8,958 Cr backlog, successful monetization/exit of Bioeq assets, OPM expands to 10.5%+, EPS reaches ₹55.00+; P/E re-rates to 25x.
• Bear Case (-25% Downside to ~₹605): Commodity price inflation squeezes fixed-price margins, execution delays extend working capital cycle, PAT contracts to ~₹220 Cr; stock derates to 18x P/E.

4. Conclusion & Verdict

• Verdict: POSSIBLE (Multibagger Score: 50/100)
• Rationale: ISGEC is a well-managed capital goods player with strong execution capabilities and healthy ROCE (17%). However, the heavy mix of lower-margin EPC business (4.7% EBIT) and moderate revenue CAGR (10-15%) make multi-fold compounding challenging in the near term. It represents a solid cyclical compounder with steady 35-70% upside potential over a 24-36 month horizon.